Patents by Inventor Andreas Wilm

Andreas Wilm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250139335
    Abstract: The present application describes a computer-implemented method for identifying target-specific T cells and their T cell Receptor (TCR) sequences. The method includes deriving single cell T cell data from a sample. The data comprises T cell profile and T cell TCR sequence. The method also includes selecting candidate T cells and their TCR sequences from the single cell T cell data using a machine learning classifier that is trained to classify T cells based on their profiles. The method may also include aggregating results over clonotypes, adding T cells with similar TCR sequences and ranking the list of candidates.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 1, 2025
    Inventors: Andreas WILM, Loan Ping ENG, Florian SCHMIDT
  • Patent number: 11597968
    Abstract: The invention relates to a method for analysing ribonucleic acid (RNA) interactions comprising: a) cross-linking base-paired nucleotides of at least one RNA molecule and/or at least one pair of RNA molecules using a tagged, reversible cross-linking agent (preferably tagged-psoralen) under ultraviolet irradiation; b) fragmenting the said cross-linked RNA molecule(s); c) using said tag to extract said cross-linked RNA fragment(s); d) ligating the said cross-linked RNA fragment(s) to produce cross-linked ligated RNA chimera(s); e) reversing the cross-linking of the said agent to the said RNA molecule(s); f) preparing a sequence library by sequencing the ligated RNA chimera molecule(s) or pair(s); and g) analysing the sequence library to determine RNA interactions. Also disclosed is a method of studying a subject by analysing RNA interactions and attributing them to a clinical picture, or a drug discovery method by attributing an efficacy score to the drug based upon determined RNA interactions.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: March 7, 2023
    Assignee: Agency for Science, Technology and Research
    Inventors: Yue Wan, Jong Ghut Ashley Aw, Niranjan Nagarajan, Andreas Wilm, Miao Sun
  • Publication number: 20190284622
    Abstract: The invention relates to a method for analysing ribonucleic acid (RNA) interactions comprising: a) cross-linking base-paired nucleotides of at least one RNA molecule and/or at least one pair of RNA molecules using a tagged, reversible cross-linking agent (preferably tagged-psoralen) under ultraviolet irradiation; b) fragmenting the said cross-linked RNA molecule(s); c) using said tag to extract said cross-linked RNA fragment(s); d) ligating the said cross-linked RNA fragment(s) to produce cross-linked ligated RNA chimera(s); e) reversing the cross-linking of the said agent to the said RNA molecule(s); f) preparing a sequence library by sequencing the ligated RNA chimera molecule(s) or pair(s); and g) analysing the sequence library to determine RNA interactions. Also disclosed is a method of studying a subject by analysing RNA interactions and attributing them to a clinical picture, or a drug discovery method by attributing an efficacy score to the drug based upon determined RNA interactions.
    Type: Application
    Filed: May 12, 2017
    Publication date: September 19, 2019
    Inventors: Yue Wan, Jong Ghut Ashley Aw, Niranjan Nagarajan, Andreas Wilm, Miao Sun